HERPES VIRUS ANTIBODIES IN PATIENTS WITH ORAL CANCER

疱疹病毒和乳头瘤病毒可在许多人类 恶性疾病，并被认为在 肿瘤的发展。这个项目将检查病人的组织。 以确定与口腔癌和白斑的作用 在这些条件下致癌的人类DNA病毒。具体目标是：1. 以确定一些口腔白斑和其他软组织疾病 与可以识别的特定病毒相关，2.要找到 疱疹病毒和病毒之间相互作用的假设的证据 乳头瘤病毒导致一些白斑的发展或 口腔癌，以及3.确定对治疗的反应和 口腔癌患者的五年生存率可以从以下方面预测 肿瘤的病毒学研究。 要使用的病毒是1型和2型单纯疱疹病毒，爱泼斯坦-巴尔病毒 和人类乳头瘤病毒1、2、4、6、11、16和18型。这些技术 将用于抗病毒抗体的酶联免疫吸附试验和放射免疫分析 对患者血清、肿瘤组织进行免疫过氧化物酶染色以确定是否存在 病毒抗原，核酸原位杂交和原位杂交 硝化棉过滤器，用于检测病毒DNA的存在。病毒抗原 DNA将在保存的组织中检测到，这些组织可以从 更早的研究。一项研究跟踪了257名白斑患者，其中 45名患者患上了癌症，另一项研究跟踪了70名口腔癌患者 癌症。这些患者的血清将被检测出水平和类型 病毒抗体。新鲜的组织和血清也将从 患有这些疾病的患者和来自新鲜和保存组织的数据 将会被比较。 本研究将加深对口腔癌发病机制的认识。 这可能会导致白斑患者更合理的治疗 指出哪些病例最有可能罹患癌症，并可能导致 为了更合理地选择口腔癌的治疗方法 肿瘤很可能对治疗有反应。

Herpesviruses and papillomaviruses can be found in a number of human malignant diseases, and are believed to play a significant role in the development of the tumors. This project will examine tissue from patients with oral cancer and leukoplakia in order to determine the role of oncogenic human DNA viruses in these conditions. The specific aims are: 1. To determine whether some oral leukoplakias and other soft tissue diseases are associated with specific viruses which can be identified, 2. To find evidence for the hypothesis that an interaction between herpesviruses and papillomaviruses is responsible for the development of some leukoplakias or oral cancers, and 3. To determine whether the response to treatment and the five-year survival rates of patients with oral cancer can be predicted from virological studies of the tumor. The viruses to be used are herpes simplex types 1 and 2, Epstein-Barr virus and human papillomaviruses types 1, 2, 4, 6, 11, 16 and 18. The techniques to be used include ELISA and radioimmunoassay of anti-virus antibody in patients' sera, immunoperoxidase staining of tumor tissue for the presence of viral antigen, and nucleic acid hybridization both in situ and on nitrocellulose filters to detect the presence of viral DNA. Viral antigens and DNA will be detected in preserved tissues which are available from earlier studies. One study followed 257 patients with leukoplakia, of whom 45 developed carcinoma, and the other study followed 70 patients with oral cancer. Sera from these patients will be tested for the levels and types of viral antibodies. Fresh tissues and sera will also be obtained from patients with these conditions and data from fresh and preserved tissue will be compared. This study will increase understanding of the pathogenesis of oral cancer. It might lead to more rational treatment of patients with leukoplakia by indicating which cases are most likely to develop carcinoma, and might lead to more rational selection of treatment of oral cancer by indicating which tumors are likely to respond to therapy.